Lund, Asger

Glucagon-like peptide 1 in health and disease

Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 543

Impaired regulation of the incretin effect in patients with type 2 diabetes

Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J., & Vilsbøll, T. (2011) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 219

The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes

Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 162

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study

Bergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., et al. (2019) · Diabetologia

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 142

The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review

Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 80

No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes

Bergmann, N. C., Gasbjerg, L. S., Heimbürger, S. M., Krogh, L. S. L., Dela, F., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 62

Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia

Suppli, M. P., Lund, A., Bagger, J. I., Vilsbøll, T., & Knop, F. K. (2016) · Medical Hypotheses

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 35

Glucagonostatic potency of GLP-1 in patients with type 2 diabetes, patients with type 1 diabetes, and healthy control subjects

Bagger, J. I., Grøndahl, M. F. G., Lund, A., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2021) · Diabetes

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 27

Once‐weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real‐world data from a diabetes out‐patient clinic

Hansen, K. B., Svendstrup, M., Lund, A., Knop, F. K., Vilsbøll, T., & Vestergaard, H. (2021) · Diabetic Medicine

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 23

Higher endogenous glucose production during OGTT vs isoglycemic intravenous glucose infusion

Lund, A., Bagger, J. I., Christensen, M., Grøndahl, M., van Hall, G., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2016) · The Journal of Clinical Endocrinology & Metabolism

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 12